A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

Joseph Tauber,Barry A. Schechter,Jason Bacharach,Melissa Toyos,Robert Smyth-Medina,Sidney L Weiss,Jodi Luchs

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

2018

Joseph Tauber
Barry A. Schechter
Jason Bacharach
Melissa Toyos
Robert Smyth-Medina
Sidney L Weiss
Jodi Luchs

Purpose The aim of this study was to evaluate the safety and efficacy of OTX-101, a clear nanomicellar aqueous solution of cyclosporine, in the treatment of dry eye disease (DED).

Keywords:

Surgery
Anesthesia
Dose-ranging study
Eye disease
Medicine
Schirmer's test
Clinical trial
Test score
Ophthalmology
Diabetes mellitus
Staining
Visual analogue scale
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations